ARTICLE | Company News
Eyetech, Valeant Pharmaceuticals deal
February 20, 2012 8:00 AM UTC
Valeant will acquire Eyetech for an undisclosed upfront payment and potential milestones. Valeant will gain Macugen pegaptanib, a pegylated oligonucleotide aptamer that binds to VEGF-165 marketed in ...